<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Immediate cephalosporin hypersensitivity: Allergy evaluation, skin testing, and cross-reactivity with other beta-lactam antibiotics
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Immediate cephalosporin hypersensitivity: Allergy evaluation, skin testing, and cross-reactivity with other beta-lactam antibiotics
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Immediate cephalosporin hypersensitivity: Allergy evaluation, skin testing, and cross-reactivity with other beta-lactam antibiotics
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Antonino Romano, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth J Phillips, MD, FRCPC, FRACP, FIDSA, FAAAAI
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anna M Feldweg, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 27, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H14737087">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cephalosporins are commonly-used antibiotics that can cause a variety of hypersensitivity reactions. This topic will discuss the allergy evaluation of patients with past immediate reactions to cephalosporins, including skin testing and graded challenges. Patients with immediate reactions to a specific cephalosporin in the past may require subsequent treatment with a different cephalosporin or a related antibiotic, such as a penicillin, carbapenem, or monobactam. Approaches to these different clinical scenarios will be presented here.
        </p>
        <p>
         The clinical manifestations and diagnosis of both immediate and delayed forms of cephalosporin hypersensitivity are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/13535.html" rel="external">
          "Cephalosporin hypersensitivity: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1165438462">
         <span class="h1">
          CHARACTERISTICS OF IMMEDIATE HYPERSENSITIVITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immediate reactions to cephalosporins are believed to be type-I, immunoglobulin E (IgE)-mediated reactions and classically begin within one hour of the last administered dose. Signs and symptoms include various combinations of flushing, urticaria, angioedema, rhinitis, bronchospasm, hypotension, and anaphylactic shock  (
         <a class="graphic graphic_table graphicRef100732" href="/z/d/graphic/100732.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2808803334">
         <span class="h2">
          Natural history
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immediate hypersensitivity to cephalosporins may be lost over time, as is documented with penicillin allergy [
         <a href="#rid1">
          1
         </a>
         ]. One study followed 72 patients with IgE-mediated hypersensitivity to cephalosporins prospectively over five years of follow-up and found that 68 percent of those sensitized only to cephalosporins no longer had evidence of skin test sensitization [
         <a href="#rid2">
          2
         </a>
         ]. Patients who were also sensitized to penicillins were less likely to convert to negative skin tests (44 percent after five years).
        </p>
        <p class="headingAnchor" id="H1858542894">
         <span class="h1">
          ALLERGY EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with past immediate reactions to cephalosporins who require subsequent use of other cephalosporins or penicillins should be evaluated by an allergy specialist.
        </p>
        <p class="headingAnchor" id="H2433924361">
         <span class="h2">
          Goals of the evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The purpose of this evaluation, which involves skin testing and graded challenge, is to determine what other drugs can be safely administered to that patient. Most patients will be able to tolerate other cephalosporins and/or penicillins. Overall &lt;2 percent of patients allergic to cephalosporins will demonstrate clinical cross-reactivity to penicillins that do not share the same side chains. However, higher rates of skin test cross-reactivity (up to 30 percent) have been demonstrated between penicillins and cephalosporins that do share similar side chains, so it is safest to advise patients to avoid both cephalosporins and penicillins after a possible immediate cephalosporin reaction, until an allergy evaluation can be performed. (See
         <a class="medical medical_review" href="/z/d/html/13535.html" rel="external">
          "Cephalosporin hypersensitivity: Clinical manifestations and diagnosis", section on 'Cross-reactivity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1573467320">
         <span class="h2">
          Whom to evaluate
         </span>
         <span class="headingEndMark">
          —
         </span>
         An evaluation for immediate hypersensitivity to cephalosporins is appropriate in any patient who experienced signs of symptoms of immediate allergy shortly (within minutes to a few hours) after receiving a cephalosporin  (
         <a class="graphic graphic_table graphicRef100732" href="/z/d/graphic/100732.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         An allergy evaluation is also recommended for children and adults with isolated urticaria and/or angioedema, even if the onset was delayed, since urticaria and angioedema can be presentations of either immediate or delayed hypersensitivity.
        </p>
        <p class="headingAnchor" id="H546114400">
         <span class="h2">
          Timing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin testing for evaluation of cephalosporin allergy is more likely to be positive the closer in time it is performed to the clinical reaction, so testing within a few months of the index reaction is ideal, although it can still be useful years later [
         <a href="#rid3">
          3-7
         </a>
         ]. However, a period of at least three to six weeks should be allowed between an immediate reaction and skin testing to the suspect drug, since skin testing may be falsely negative if performed too soon [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2914347900">
         <span class="h1">
          ALLERGENIC COMPONENTS OF CEPHALOSPORINS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients may develop immunoglobulin E (IgE) antibodies against antigenic determinants that are unique to cephalosporins or to determinants that are shared with other beta-lactam drugs, particularly the penicillins [
         <a href="#rid9">
          9-19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2767711153">
         <span class="h2">
          Potential allergenic components
         </span>
         <span class="headingEndMark">
          —
         </span>
         The core structure of both penicillins and cephalosporins contains a four-membered beta-lactam ring  (
         <a class="graphic graphic_figure graphicRef69298" href="/z/d/graphic/69298.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         Cephalosporins also contain a six-membered dihydrothiazine ring [
         <a href="#rid14">
          14-19
         </a>
         ], which is not usually allergenic in its intact form and breaks down rapidly after administration [
         <a href="#rid15">
          15,16
         </a>
         ]. In vitro studies have shown that patients may be sensitized to any of the following [
         <a href="#rid10">
          10,20-24
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The entire cephalosporin molecule that includes the cephalosporin-specific dihydrothiazine ring [
         <a href="#rid11">
          11
         </a>
         ], based on a study showing that the most common pattern of reactivity was being skin-test positive to the culprit cephalosporin only and not to cephalosporins that share R1 or R2 side groups [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Either of the side chain groups (R1 and R2), with sensitization to R1, which comes off the shared beta-lactam ring, being significantly more common [
         <a href="#rid14">
          14,17-19,26
         </a>
         ] based on studies that utilized skin testing and challenges  (
         <a class="graphic graphic_figure graphicRef69298" href="/z/d/graphic/69298.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid6">
          6,7,25,27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The core beta-lactam ring or metabolites of it (uncommon) [
         <a href="#rid14">
          14,17-19,26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1156344229">
         <span class="h2">
          Side chain groups
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain cephalosporins share structurally similar R1 side chain groups or R2 side chain groups with other cephalosporins or with specific penicillins [
         <a href="#rid9">
          9,12,14,16-19,26
         </a>
         ]. Sensitization to the R1 side chain group of cephalosporins, in particular, has proved to be important in determining cross-reactivity with penicillins [
         <a href="#rid2">
          2-4,6,7,27-29
         </a>
         ] and among cephalosporins [
         <a href="#rid2">
          2,4,6,7,16,25,27,29-33
         </a>
         ].
        </p>
        <p>
         There are several different lists and graphics in the published literature identifying groups of cephalosporins with similar or identical R1 or R2 side chains, and significant variability among the groupings. This variability has arisen from several factors, including whether the groupings are based solely on the chemical structures of the drugs or also incorporates clinical cross-reactivity (which, in turn, can be based on skin testing or challenge or both), available studies evaluating clinical relevance at the time the tables were created, and geographical differences in sensitization patterns around the world. The tables provided here should be used to select an alternative cephalosporin, which must then be evaluated with skin testing and/or challenge.
        </p>
        <p>
         The tables can be used to choose possible alternatives to a given culprit drug:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Culprit cephalosporin was a first generation agent  (
         <a class="graphic graphic_table graphicRef122928" href="/z/d/graphic/122928.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Culprit cephalosporin was a second generation agent  (
         <a class="graphic graphic_table graphicRef122929" href="/z/d/graphic/122929.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Culprit cephalosporin was a third generation agent  (
         <a class="graphic graphic_table graphicRef122930" href="/z/d/graphic/122930.html" rel="external">
          table 4
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Culprit cephalosporin was a fourth or fifth generation agent  (
         <a class="graphic graphic_table graphicRef122931" href="/z/d/graphic/122931.html" rel="external">
          table 5
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         The choice of alternative cephalosporins to include in skin testing is discussed further below. (See
         <a class="local">
          'What to include'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4247815458">
         <span class="h3">
          R1 side chains
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinically important R1 side chain groupings include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs that have an identical R1 group and show risk for clinical cross-reactivity:
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          Ceftriaxone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">
          cefotaxime
         </a>
         ,
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         ,
         <a class="drug drug_general" data-topicid="9224" href="/z/d/drug information/9224.html" rel="external">
          cefpodoxime
         </a>
         , cefditoren, cefodizime, ceftizoxime, cefpirome, and cefetamet (the last five drugs are not available in the United States).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some studies that have applied skin testing and challenge suggest cross-reactivity between the above listed cephalosporins that share the complete R1 group and cephalosporins that share the methoxyimino component in the R1 position, such as
         <a class="drug drug_general" data-topicid="9230" href="/z/d/drug information/9230.html" rel="external">
          cefuroxime
         </a>
         (
         <a class="graphic graphic_figure graphicRef53755" href="/z/d/graphic/53755.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid2">
          2,4,7,16,25,30,33
         </a>
         ]. Specifically, cross-reactivity among cefuroxime,
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">
          cefotaxime
         </a>
         , cefodizime, and
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         has been reported [
         <a href="#rid2">
          2,4,7,16,25,30-33
         </a>
         ]. Sensitization to this group of cephalosporins is prevalent in some European countries (eg, Italy, Spain, and Denmark) [
         <a href="#rid2">
          2-4,25,28-31,34
         </a>
         ] but appears to be less common in other parts of the world.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          Ceftazidime
         </a>
         has an R1 side chain that is slightly different from those of the aforementioned cephalosporins because it contains an alkoxyimino group instead of a methoxyimino group  (
         <a class="graphic graphic_figure graphicRef53755" href="/z/d/graphic/53755.html" rel="external">
          figure 2
         </a>
         ). Patients sensitized to the R1 side chain of the above cephalosporins or the methoxyimino group as evidenced by cross-reactivity with
         <a class="drug drug_general" data-topicid="9230" href="/z/d/drug information/9230.html" rel="external">
          cefuroxime
         </a>
         can usually tolerate ceftazidime [
         <a href="#rid33">
          33,35
         </a>
         ]. However, this is not always the case [
         <a href="#rid2">
          2,4,7,25,29-31
         </a>
         ], and skin testing should be performed for the specific desired alternative cephalosporin.
        </p>
        <p>
        </p>
        <p>
         All of the aminopenicillins and corresponding aminocephalosporins are potentially cross-reactive:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The following drugs share an R1 side chain group with
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         :
         <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">
          Cephalexin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9211" href="/z/d/drug information/9211.html" rel="external">
          cefaclor
         </a>
         , cephradine, cephaloglycin, and loracarbef  (
         <a class="graphic graphic_figure graphicRef65497" href="/z/d/graphic/65497.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid14">
          14,17-19
         </a>
         ]. Cross-reactivity between cephalexin or cefaclor and ampicillin has been reported [
         <a href="#rid3">
          3,4,6,7,13,25,26,28,29
         </a>
         ], and cross-reactivity between cephalexin and cefaclor has also been demonstrated in cephalexin-allergic subjects [
         <a href="#rid6">
          6,27,36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The following drugs share an R1 side chain group with
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         :
         <a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">
          Cefadroxil
         </a>
         , cefatrizine, and
         <a class="drug drug_general" data-topicid="9225" href="/z/d/drug information/9225.html" rel="external">
          cefprozil
         </a>
         (
         <a class="graphic graphic_figure graphicRef65497" href="/z/d/graphic/65497.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid12">
          12,14,17-19,26
         </a>
         ]. Cross-reactivity between cefadroxil and amoxicillin has been observed in subjects allergic to amoxicillin [
         <a href="#rid37">
          37-39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          Amoxicillin
         </a>
         and
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         and their respective R1 sharing aminocephalosporins differ from each other only by a hydroxy (-OH) group on the R1 chain. It should be assumed that a high rate of cross-reactivity exists between ampicillin and amoxicillin and that where cross-reactivity has been demonstrable between any aminopenicillin and aminocephalosporin, that this would apply to the entire group [
         <a href="#rid25">
          25,35,39-43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3476317827">
         <span class="h3">
          Cefazolin has unique side chains
         </span>
         <span class="headingEndMark">
          —
         </span>
         Note that
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         , which is the most common cephalosporin to cause anaphylaxis in the United States, has unique R1 and R2 side chain groups and does not appear to cross-react with the other cephalosporins except ceftezole (a first generation agent that is only available in Italy, South Korea, and some Southeastern Asian countries) [
         <a href="#rid17">
          17,18
         </a>
         ]. Ceftezole shares an identical R1 side chain and a similar R2 side chain with cefazolin [
         <a href="#rid18">
          18
         </a>
         ]. Several studies suggest that skin test-positive patients with past immediate reactions to cefazolin often tolerate all other cephalosporins (except ceftezole) and other beta-lactams [
         <a href="#rid6">
          6,7,25,27,44-52
         </a>
         ]. However, allergy evaluation is still advised whenever possible because there are rare exceptions.
        </p>
        <p class="headingAnchor" id="H3422353990">
         <span class="h1">
          SKIN TESTING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple studies have shown that skin testing in patients with past immediate reactions to cephalosporins can be used to confirm sensitization to the suspect drug and to identify alternative cephalosporins that can then be given in challenge procedures to prove tolerance [
         <a href="#rid6">
          6,7,25,27,33,35,44,46-62
         </a>
         ]. However, it is important to appreciate that cephalosporin skin testing has several limitations.
        </p>
        <p class="headingAnchor" id="H840892074">
         <span class="h2">
          Limitations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin testing with cephalosporins is not as well-validated as penicillin skin testing for the following reasons:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The allergenic determinants of cephalosporins have not been well-defined, unlike those for penicillins.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reagents are not commercially available for testing to cephalosporin-protein conjugates, as they are for penicillins.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The positive and negative predictive values of testing have not been fully established.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There are regional differences in patterns of sensitization to cephalosporins around the world, such that research findings from one area may not be generalizable to other populations. (See
         <a class="local">
          'Groups of cephalosporins less likely to cross react'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the United States, only cephalosporins that already come as a sterile parenteral formulation are used for skin testing, limiting the scope of the evaluation. However, other countries have additional options. (See
         <a class="local">
          'Preparation of reagents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H556904017">
         <span class="h2">
          Technique
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prick/puncture technique is performed first. If prick/puncture tests are negative, then intradermal testing is performed [
         <a href="#rid8">
          8,63-66
         </a>
         ]. A general discussion of skin testing techniques, including preparation of the patient and contraindications, is found separately. (See
         <a class="medical medical_review" href="/z/d/html/5541.html" rel="external">
          "Overview of skin testing for IgE-mediated allergic disease"
         </a>
         .)
        </p>
        <p>
         The author's approach is to spread testing over three separate days to reduce the risk of inducing systemic reactions. Testing with penicillin reagents is performed on one day,
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         and
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         on another, and testing to cephalosporins on a third day [
         <a href="#rid3">
          3,4
         </a>
         ]. However, this may not be feasible in most settings. Therefore, skin tests with all reagents can be performed on one day. Both approaches are safe, and systemic reactions to the testing itself are rare.
        </p>
        <p class="headingAnchor" id="H500014192">
         <span class="h3">
          What to include
         </span>
         <span class="headingEndMark">
          —
         </span>
         To perform a comprehensive evaluation of a suspected immediate cephalosporin allergy, we suggest prick/puncture skin testing, followed if negative by intradermal skin testing to all of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Positive histamine and negative
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         controls to ensure normal skin reactivity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The cephalosporin(s) implicated in the past reaction. A complete listing of parenteral and oral cephalosporins is shown in the table  (
         <a class="graphic graphic_table graphicRef115428" href="/z/d/graphic/115428.html" rel="external">
          table 6
         </a>
         ). Only parenteral drugs are used for skin testing in the United States. (See
         <a class="local">
          'Preparation of reagents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One or more alternative cephalosporins with dissimilar side chains, especially in the R1 position, that the patient could potentially receive instead, which can be selected using the tables below.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Culprit cephalosporin was a first generation agent  (
         <a class="graphic graphic_table graphicRef122928" href="/z/d/graphic/122928.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Culprit cephalosporin was a second generation agent  (
         <a class="graphic graphic_table graphicRef122929" href="/z/d/graphic/122929.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Culprit cephalosporin was a third generation agent  (
         <a class="graphic graphic_table graphicRef122930" href="/z/d/graphic/122930.html" rel="external">
          table 4
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Culprit cephalosporin was a fourth or fifth generation agent  (
         <a class="graphic graphic_table graphicRef122931" href="/z/d/graphic/122931.html" rel="external">
          table 5
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         (See
         <a class="local">
          'Groups of cephalosporins less likely to cross react'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The classic penicillin reagents: the major determinant (
         <a class="drug drug_general" data-topicid="15949" href="/z/d/drug information/15949.html" rel="external">
          penicilloyl-polylysine
         </a>
         [PPL] or benzylpenicilloyl-octa-L-lysine), the minor determinant mixture (MDM) or a minor determinant (MD; sodium benzylpenilloate) if available, and benzylpenicillin (also called
         <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">
          penicillin G
         </a>
         ). Note that it would not be necessary to include these if the patient has tolerated penicillins or
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         <strong>
          since
         </strong>
         the cephalosporin reaction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          Ampicillin
         </a>
         and
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         (where parenteral formulations are available for use in testing): The aminopenicillins are included to detect patients who are sensitized to side chain groups that are shared by these and some cephalosporins  (
         <a class="graphic graphic_figure graphicRef65497" href="/z/d/graphic/65497.html" rel="external">
          figure 3
         </a>
         ). If the patient tests positive to one or both of these, then the related antibiotics should be excluded from the list of potential alternative cephalosporins for evaluation. Alternatives drugs should be chosen instead from one of the following:
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9230" href="/z/d/drug information/9230.html" rel="external">
          cefuroxime
         </a>
         ,
         <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">
          cefotaxime
         </a>
         ,
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         , cefodizime, or
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         .
        </p>
        <p>
        </p>
        <p>
         The full panel of tests may not be clinically indicated in all situations. For example, if a patient developed hives to
         <a class="drug drug_general" data-topicid="9224" href="/z/d/drug information/9224.html" rel="external">
          cefpodoxime
         </a>
         but had no known adverse reaction to penicillin, and the clinician simply wanted to determine if it was safe to treat the patient with penicillins in the future, then it might be sufficient just to skin test with the classic penicillin reagents. Approaches to common clinical scenarios are discussed below. (See
         <a class="local">
          'Use of related antibiotics in cephalosporin-allergic patients'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3998054961">
         <span class="h3">
          Concentrations for skin testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most cephalosporins, 20 mg/mL is a non-irritating concentration [
         <a href="#rid25">
          25,44,67-70
         </a>
         ], which is endorsed by European position papers for testing of cephalosporin and other beta-lactam allergy [
         <a href="#rid8">
          8,68,71
         </a>
         ]. An exception is
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         , for which we propose a skin testing solution of 2 mg/mL, as higher concentrations can be irritating. For patients with prior severe anaphylaxis to a cephalosporin, prick testing is always performed first, and solutions for initial intradermal testing can be diluted 10- to 1000-fold further, to reduce the risk of inducing a systemic reaction.
        </p>
        <p class="headingAnchor" id="H2446252984">
         <span class="h3">
          Preparation of reagents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Testing solutions of cephalosporins (and penicillins) should be freshly prepared on the day of testing [
         <a href="#rid3">
          3,4,25,30,69
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For injectable cephalosporins, the intravenous formulation is used  (
         <a class="graphic graphic_table graphicRef115428" href="/z/d/graphic/115428.html" rel="external">
          table 6
         </a>
         ). In the United States, intravenous preparations of cephalosporins are the
         <strong>
          only
         </strong>
         form used for skin testing, because intradermal skin testing using solutions prepared from oral tablets or capsules is not generally performed outside of research settings. In addition, oral liquid suspensions are not appropriate for intradermal skin testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In many other countries, oral cephalosporins are solubilized and filter-sterilized for use in skin testing. The powder contained in capsules or obtained by removing the external layer of tablets with a scalpel can be used. After weighing the powder, solutions are prepared under a laminar flow hood [
         <a href="#rid72">
          72,73
         </a>
         ] and are filter-sterilized through single-use devices (0.20 micrometer syringe filter) [
         <a href="#rid4">
          4,6
         </a>
         ]. These approaches have not been standardized, and studies suggest that the negative predictive value is significantly less than 100 percent for oral aminocephalosporins prepared in this way [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3667956976">
         <span class="h2">
          Interpretation
         </span>
        </p>
        <p class="headingAnchor" id="H143239526">
         <span class="h3">
          Positive results
         </span>
         <span class="headingEndMark">
          —
         </span>
         A positive skin test (on the volar forearm) to a cephalosporin drug may be defined as a wheal &gt;3 mm in diameter for skin prick testing, or any increase by 3 mm or more in the diameter of the wheal produced by the injection for intradermal testing, with surrounding erythema, that develops within 20 minutes of placement [
         <a href="#rid4">
          4,8,73
         </a>
         ]. A positive skin test result implies the presence of drug-specific immunoglobulin E (IgE) antibodies and potential clinical allergy. Cephalosporins that yield positive skin tests should not be given except through a desensitization protocol.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As with skin testing for most drugs, the positive predictive value has not been precisely defined, because this would require administering the drug to large numbers of skin test-positive patients with no personal benefit to confirm that they are truly reactive, which has been generally avoided for ethical reasons.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The sensitivity of skin testing with cephalosporins has been estimated in some studies involving children [
         <a href="#rid3">
          3,74
         </a>
         ], both children and adults [
         <a href="#rid31">
          31
         </a>
         ], and adults [
         <a href="#rid4">
          4,6,7
         </a>
         ], with histories of immediate reactions to these beta-lactams. The rate of positive responses to cephalosporin skin tests ranged from 8.9 percent (22 of 245 subjects) [
         <a href="#rid7">
          7
         </a>
         ] to 72.1 percent (31 of 43) [
         <a href="#rid3">
          3
         </a>
         ], although patients with positive test results were not challenged to confirm if these were true positives (for the ethical reasons just mentioned). The highest rate was found in a study from the author's center [
         <a href="#rid3">
          3
         </a>
         ], in which 30 (70 percent) of the 43 children with immediate reactions to cephalosporins had experienced anaphylaxis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3867460373">
         <span class="h3">
          Negative results
         </span>
         <span class="headingEndMark">
          —
         </span>
         If prick/puncture and intradermal test responses are negative, it does not conclusively prove that the patient does not have specific IgE antibodies to the cephalosporin in its native state [
         <a href="#rid4">
          4
         </a>
         ]. In addition, the patient could still have IgE antibodies against a metabolite or metabolite-protein complex not detected by the testing, and the negative predictive value of cephalosporin skin testing is not well-defined. Therefore, in patients with a history suggestive of a higher risk or IgE-mediated reaction, negative skin testing should be followed by graded challenge before the patient can be advised that it is safe to receive that cephalosporin again.
        </p>
        <p class="headingAnchor" id="H1664359820">
         <span class="h1">
          IN VITRO TESTING
         </span>
         <span class="headingEndMark">
          —
         </span>
         In vitro assays for cephalosporin-specific immunoglobulin E (IgE) are not commonly used, because they are less sensitive than skin testing and not widely available [
         <a href="#rid4">
          4,8,64
         </a>
         ]. The only commercially-available cephalosporin-specific IgE test is for
         <a class="drug drug_general" data-topicid="9211" href="/z/d/drug information/9211.html" rel="external">
          cefaclor
         </a>
         , and that is rarely obtained because cefaclor is not widely used in the United States, and because of the negative predictive value of cefaclor IgE for both cefaclor and related aminocephalosporins, such as
         <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">
          cephalexin
         </a>
         , is not high.
        </p>
        <p>
         In a series of the author's concerning 59 subjects (31 adults and 28 children) with histories of immediate reactions to
         <a class="drug drug_general" data-topicid="9211" href="/z/d/drug information/9211.html" rel="external">
          cefaclor
         </a>
         , the ImmunoCAP was positive in only 16 subjects (12 adults and 4 children), whereas skin tests were positive in 44 (22 adults and 22 children). Of the 16 subjects positive to cefaclor ImmunoCAP, 14 were also skin test positive; the remaining 2 (both adults) were skin test negative [
         <a href="#rid75">
          75
         </a>
         ]. A few studies have performed investigational assays for IgE to cephalosporins other than cefaclor in samples larger than 10 patients [
         <a href="#rid4">
          4,10,20,21,29,30,34,76,77
         </a>
         ].
        </p>
        <p>
         In some centers, flow cytometric basophil activation tests (BAT) for drug allergy are performed [
         <a href="#rid50">
          50,51,78-84
         </a>
         ]. This is not widely available in the United States, and additional comprehensive studies in large samples are required in order to further validate the technique and provide a definitive assessment of its sensitivity [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1573854653">
         <span class="h1">
          GRADED CHALLENGE (TEST DOSING)
         </span>
         <span class="headingEndMark">
          —
         </span>
         A graded challenge, also called a test dose, does not modify a patient's response to a drug, so patients who tolerate challenge prove that they are not allergic to the drug in question. Graded challenges often require experience to interpret properly, because patients can develop nonspecific or anxiety-related symptoms.
        </p>
        <p class="headingAnchor" id="H123358482">
         <span class="h2">
          Indications and precautions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Graded challenge is appropriate
         <strong>
          only
         </strong>
         when immediate allergy to the tested drug is judged to be unlikely after careful consideration of the details of the history [
         <a href="#rid36">
          36,66,86
         </a>
         ]. In the United States, graded challenges are used to confirm tolerance, whereas European guidelines also emphasize a role for graded challenge in establishing a firm diagnosis of beta-lactam hypersensitivity in selected cases of patients with negative skin tests and reliable in vitro tests [
         <a href="#rid8">
          8,63,64,87
         </a>
         ]. Note that challenges with cephalosporins can reasonably be expected to elicit reactions more often than challenges with penicillins, because the negative predictive value of cephalosporin skin testing is not as well-defined and likely lower than that of penicillin skin testing. For cephalosporins, a drug is most likely to be tolerated on challenge if it has different R1 and R2 side chains from the cephalosporin that caused the index reaction and yielded negative results on skin testing. All challenges in patients with a higher-risk history should be confirmed by a graded rather than single-dose challenge. (See
         <a class="local">
          'Technique'
         </a>
         below.)
        </p>
        <p>
         Test doses may be administered by an allergy specialist (preferable) or a member of the general medical team [
         <a href="#rid88">
          88
         </a>
         ]. The purpose of a test dose is to expose the patient to a small amount of drug, followed by a period of close observation, in case there is a reaction.
        </p>
        <p>
         Because graded challenges
         <strong>
          will not prevent
         </strong>
         <strong>
          or circumvent an immediate allergic reaction
         </strong>
         , the clinician must be prepared to recognize and treat such a reaction if one occurs. An H1 antihistamine (eg,
         <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">
          cetirizine
         </a>
         10 mg orally) and
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         for intramuscular injection should be available, preferably in the form of an autoinjector to ensure the appropriate dose is given. If a fixed-dose epinephrine autoinjector is not being used, the appropriate concentration and dose of intramuscular epinephrine for that patient should be calculated in advance so that there are no delays or dosing errors if epinephrine is needed. Proper dosing of epinephrine and anaphylaxis management is described in the tables for adults  (
         <a class="graphic graphic_table graphicRef58346" href="/z/d/graphic/58346.html" rel="external">
          table 7
         </a>
         ) and children  (
         <a class="graphic graphic_table graphicRef74242" href="/z/d/graphic/74242.html" rel="external">
          table 8
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1918429288">
         <span class="h2">
          Technique
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior to graded challenges, patients are usually
         <strong>
          not
         </strong>
         pretreated with antihistamines or glucocorticoids, because antihistamines may mask early signs of an allergic reaction. However, if a patient is already receiving a daily antihistamine for allergic rhinitis or another disorder, it is not necessary to withhold it (unless skin testing is being performed prior to challenge). We usually withhold beta-adrenergic blocking medications for 24 hours before the first dose, if feasible, as these medications can interfere with treatment of anaphylaxis, should a reaction occur. Patients with asthma, chronic obstructive lung disease, or other chronic pulmonary diseases should be optimally controlled prior to undergoing challenge.
        </p>
        <p>
         The patient is assessed for symptoms, and vital signs are recorded every 30 minutes. More information about graded challenges, including interpretation of subjective symptoms, is reviewed separately. (See
         <a class="local">
          'Graded challenge (Test dosing)'
         </a>
         above.)
        </p>
        <p>
         Patients who develop symptoms consistent with an immunoglobulin E (IgE)-mediated reaction during or shortly after the graded challenge (within a few hours of receiving the full dose) should be treated appropriately and should not receive further drug. These patients should be considered allergic to that agent and it should be avoided. If that specific drug is critical and there is no equivalent alternative, it can be administered using a desensitization protocol. (See
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1893082793">
         <span class="h3">
          Oral protocols
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most graded challenges in the outpatient setting are performed with oral cephalosporins. A typical oral challenge consists of two steps. In a study including both hospitalized patients and outpatients in an allergy/immunology clinic, a simple two-step graded challenge in low-risk patients was as safe as three- or four-step challenges [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
         The first step is to administer 1/4
         <sup>
          th
         </sup>
         of a full dose (can be prepared with a pill cutter) or 1/10
         <sup>
          th
         </sup>
         (usually prepared with the liquid oral suspension) of the full dose. If no reaction occurs, the full therapeutic dose is administered 30 to 60 minutes later.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An example of an oral test dose to
         <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">
          cephalexin
         </a>
         starting with 1/10
         <sup>
          th
         </sup>
         of a dose would be the following: Give 25 mg (ie, 0.5 mL of the 250 mg/5 mL suspension, given with a glass of water), followed by one hour of observation. If no symptoms, give 250 mg, followed by one hour of observation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1478028157">
         <span class="h3">
          Intravenous or intramuscular protocols
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravenous (IV) or intramuscular graded challenges are used less often. In most cases, a test dose can be 1/10
         <sup>
          th
         </sup>
         (10 percent) of the full therapeutic dose for that patient. If no reaction occurs, the full therapeutic dose (or 9/10
         <sup>
          th
         </sup>
         of the full dose) is administered 30 to 60 minutes later.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An example of an IV test dose to
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         starting with 1/10
         <sup>
          th
         </sup>
         of a dose would be the following: Give 100 mg, followed by one hour of observation. If no symptoms, give 1000 mg, followed by one hour of observation. The next dose after that is given normally when it is due.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For IV challenges, the test dose solution should not be significantly more dilute than the normal preparation, because patients may not react if the concentration is dramatically altered [
         <a href="#rid36">
          36,90
         </a>
         ]. Thus, the 1/10
         <sup>
          th
         </sup>
         (10 percent) dose can be withdrawn from a full-strength bag with a syringe and administered by slow IV push (usually about 1 mL/min), followed in one hour (if tolerated) by the remaining 90 percent. Other methods of administering test doses and additional safety issues surrounding test dosing policies have been described [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         If it is necessary to perform challenges with the culprit cephalosporins in high-risk subjects (eg, those who experienced severe reactions), an initial dose of 1/100
         <sup>
          th
         </sup>
         of the therapeutic one is administered. In cases with negative results, one hour later a dose of 1/10
         <sup>
          th
         </sup>
         and, if the result is again negative, after another hour a full therapeutic dose [
         <a href="#rid4">
          4
         </a>
         ]. Note that a 2020 European position paper suggests using different challenge protocols depending on the patient's risk profile [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2125261656">
         <span class="h2">
          Risk of resensitization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Questions sometimes arise about the risk of resensitizing a patient as a result of an oral challenge or treatment with a full course of oral antibiotics. Studies suggest that resensitization occurs in &lt;1 percent of patients exposed through oral administration and doesn't always correlate with clinical reactivity, and so the practice of retesting patients following negative oral challenge or oral treatment is not standard. However, there may be certain high-risk groups of patients, such as patients with cystic fibrosis who receive multiple courses of intravenous antibiotics, in whom patients with past severe anaphylaxis might become resensitized after treatment. The author usually retests patients who experienced severe reactions after four weeks to determine if there has been resensitization after previous loss of sensitivity [
         <a href="#rid4">
          4,8,63,64
         </a>
         ]. This issue has been studied more extensively in penicillin-allergic patients. (See
         <a class="medical medical_review" href="/z/d/html/16503.html" rel="external">
          "Penicillin skin testing", section on 'Resensitization'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H850610148">
         <span class="h1">
          USE OF RELATED ANTIBIOTICS IN CEPHALOSPORIN-ALLERGIC PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The groups of antibiotics that are related to cephalosporins are penicillins, carbapenems, and monobactams  (
         <a class="graphic graphic_figure graphicRef79230" href="/z/d/graphic/79230.html" rel="external">
          figure 4
         </a>
         ). An approach for the use of each of these related drugs in a cephalosporin-allergic patient is outlined below.
        </p>
        <p class="headingAnchor" id="H3880190196">
         <span class="h2">
          Other cephalosporins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with past cephalosporin reactions can receive other cephalosporins safely. Although the side chain groups of cephalosporins are believed to be important in determining cross-reactivity, it is important for clinicians to appreciate that side chain similarities alone cannot be relied on to predict cross-reactivity accurately [
         <a href="#rid2">
          2,4,6,7,16,25,27,29-31,33,48
         </a>
         ]. Rather, in studies of at least five cephalosporin-allergic subjects [
         <a href="#rid6">
          6,7,25,27,35,44,48,49,51
         </a>
         ], these similarities are best used to select structurally different cephalosporins from the one that caused the initial reaction, which are then evaluated with skin testing and challenge to determine patient tolerance.
        </p>
        <p class="headingAnchor" id="H4204882080">
         <span class="h3">
          Algorithmic approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         An abbreviated algorithm, which does not require testing to the full panel of penicillin and cephalosporin reagents but instead focuses on identifying an alternative cephalosporin that the patient can safely receive, is shown  (
         <a class="graphic graphic_algorithm graphicRef122623" href="/z/d/graphic/122623.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clinician should choose one or more alternative cephalosporins that have different side chains, especially in the R1 position, from the cephalosporin that caused the past reaction. However, a similar side chain should not absolutely exclude a drug from consideration if it is the most appropriate drug for the clinical situation [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skin testing should be performed to the desired cephalosporin. (See
         <a class="local">
          'Skin testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the results are positive, then the patient should be assumed to be allergic to the desired cephalosporin and it should only be administered using a desensitization protocol.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the results are negative, then the desired cephalosporin can be administered by graded challenge to confirm that the drug is tolerated. (See
         <a class="local">
          'Graded challenge (Test dosing)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         According to the American practice parameter, an alternative approach is giving the selected cephalosporin via a graded challenge, without performing any skin tests [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="local">
          'Graded challenge (Test dosing)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1343979907">
         <span class="h3">
          Groups of cephalosporins less likely to cross react
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a study from the author's center that assessed cross-reactivity among cephalosporins, groupings of cephalosporins were identified that were useful for selecting alternative cephalosporins that patients are likely to tolerate [
         <a href="#rid25">
          25
         </a>
         ]. In this study, 102 cephalosporin-allergic adults underwent extensive cephalosporin skin testing (and cefaclor-specific immunoglobulin E [IgE] assays), followed by 323 challenges with different cephalosporins to determine patterns of tolerance. Four groups were identified:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Group A (73 subjects) consisted of patients with positive skin tests to one or more of the cephalosporins with methoxyimino groups in the R1 position (
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9230" href="/z/d/drug information/9230.html" rel="external">
          cefuroxime
         </a>
         ,
         <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">
          cefotaxime
         </a>
         ,
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         , cefodizime) or
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         (
         <a class="graphic graphic_figure graphicRef53755" href="/z/d/graphic/53755.html" rel="external">
          figure 2
         </a>
         ). These patients underwent skin tests and, in case of negative results, challenges with
         <a class="drug drug_general" data-topicid="9211" href="/z/d/drug information/9211.html" rel="external">
          cefaclor
         </a>
         ,
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9227" href="/z/d/drug information/9227.html" rel="external">
          ceftibuten
         </a>
         . All patients tolerated these alternative cephalosporins using this approach. In this group, 32 of 73 patients had positive skin testing to more than one of the group A cephalosporins (ie, the culprit group A cephalosporin and another one that shared a methoxyimino group). Note that despite the different R1 group of ceftazidime, a similar pattern of tolerance with cefaclor, cefazolin, and ceftibuten was observed. The frequency of sensitization to the group A cephalosporins in the United States appears to be lower than that in Europe.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Group B (13 subjects) consisted of patients with positive skin tests to the aminocephalosporins
         <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">
          cephalexin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9211" href="/z/d/drug information/9211.html" rel="external">
          cefaclor
         </a>
         , or
         <a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">
          cefadroxil
         </a>
         (
         <a class="graphic graphic_figure graphicRef65497" href="/z/d/graphic/65497.html" rel="external">
          figure 3
         </a>
         ). These patients underwent skin tests and, in case of negative results, challenges with
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9230" href="/z/d/drug information/9230.html" rel="external">
          cefuroxime
         </a>
         ,
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9227" href="/z/d/drug information/9227.html" rel="external">
          ceftibuten
         </a>
         . All patients tolerated ceftriaxone and cefuroxime (both in group A), as well as cefazolin and ceftibuten. In this group, only 2 of 13 patients had positive skin testing to more than one of the group B aminocephalosporins.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Group C (7 patients) tested positive to cephalosporins
         <strong>
          other than
         </strong>
         those belonging to the aforementioned groups (ie, cefoperazone, cefamandole, and
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         )  (
         <a class="graphic graphic_figure graphicRef113554" href="/z/d/graphic/113554.html" rel="external">
          figure 5
         </a>
         ). One subject who had reacted to cefoperazone tested positive to both cefoperazone and cefamandole, which share an identical R2 side chain. These patients were then challenged with cephalosporins to which they were skin test negative and no reactions occurred.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Group D (9 participants) tested positive to cephalosporins belonging to two different groups. These patients were also challenged with cephalosporins to which they were skin test negative and no reactions occurred.
        </p>
        <p>
        </p>
        <p>
         The groupings described above have been observed in several European countries. Similar studies have been performed very rarely in North American populations or in other parts of the world [
         <a href="#rid7">
          7
         </a>
         ], so clinicians should only use these groupings to choose alternative agents that are then evaluated with skin testing or challenge to determine if the patient can tolerate them.
        </p>
        <p class="headingAnchor" id="H916287682">
         <span class="h2">
          The same cephalosporin that caused the reaction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rarely, a patient requires the same cephalosporin to which there is evidence of IgE-mediated allergy. A formal desensitization protocol should be performed in this situation. The procedure described for penicillin desensitization would be appropriate. (See
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3743047801">
         <span class="h2">
          Penicillins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with immediate reactions to cephalosporins and
         <strong>
          no
         </strong>
         history of reacting to penicillins will tolerate penicillins. However, there are patients who react to both groups of drugs and there are at least three allergenic determinants that are shared by penicillins and cephalosporins that may be responsible for this cross-reactivity:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Side chain groups
         </strong>
         – Side chain groups may be the most common source of cross-reactivity between cephalosporins and penicillins. In one study, patients with past reactions to cephalosporins with similar or identical side chains with penicillins demonstrated a threefold increased incidence of positive results on allergy tests (skin testing or in vitro testing) with that penicillin [
         <a href="#rid28">
          28
         </a>
         ].
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          Amoxicillin
         </a>
         has the same side chain as
         <a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">
          cefadroxil
         </a>
         ,
         <a class="drug drug_general" data-topicid="9225" href="/z/d/drug information/9225.html" rel="external">
          cefprozil
         </a>
         , and cefatrizine [
         <a href="#rid12">
          12,14,17-19,26
         </a>
         ].
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          Ampicillin
         </a>
         has the same side chain as
         <a class="drug drug_general" data-topicid="9211" href="/z/d/drug information/9211.html" rel="external">
          cefaclor
         </a>
         ,
         <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">
          cephalexin
         </a>
         , cephradine, cephaloglycin, and loracarbef (no longer available in the United States) [
         <a href="#rid14">
          14,17-19,26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Small moieties
         </strong>
         – Small moieties shared by cephalosporins and penicillins can also be allergenically important. In one study, a population of IgE antibodies recognizing a methylene group present in both cephalothin and benzylpenicillin was identified in patient sera [
         <a href="#rid20">
          20
         </a>
         ]. Positive skin tests to both benzylpenicillin and cephalothin have been observed in such patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Beta-lactam ring
         </strong>
         – A very small percentage of patients with primary cephalosporin reactions may be sensitized to the beta-lactam core that is common to cephalosporins, penicillins, monobactams, and carbapenems  (
         <a class="graphic graphic_figure graphicRef79230" href="/z/d/graphic/79230.html" rel="external">
          figure 4
         </a>
         ) [
         <a href="#rid28">
          28
         </a>
         ]. Patients with this type of allergy would have positive allergy tests to all beta-lactams [
         <a href="#rid28">
          28,42,91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H650562618">
         <span class="h3">
          Algorithmic approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         If a cephalosporin-allergic patient requires a penicillin, then penicillin allergy testing is indicated to guide management as follows  (
         <a class="graphic graphic_algorithm graphicRef122624" href="/z/d/graphic/122624.html" rel="external">
          algorithm 2
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Negative results on penicillin skin testing indicate that the patient's reaction to the cephalosporin was probably due to a unique cephalosporin determinant. Therefore, the patient is not at increased risk for reacting to a penicillin, provided that penicillin does not share a side chain with the cephalosporin that caused the initial reaction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Positive results on penicillin skin testing indicate that the patient may be reactive to the beta-lactam core, provided that the penicillin and cephalosporin in question do not share similar side chains. Because selective recognition by IgE antibodies of the beta-lactam ring is very rare [
         <a href="#rid14">
          14
         </a>
         ], the clinical history and risk stratification should be taken into account in this situation. The possibility of a separate but concomitant sensitization to both the culprit cephalosporin and the selected penicillin should also be taken into account [
         <a href="#rid14">
          14
         </a>
         ]. Thus, the patient should undergo skin tests with
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         and/or carbapenems and, if negative, she/he can be treated with these alternative beta-lactams. In case of positive results, she/he can be treated with a non-beta-lactam antibiotic or desensitized to the desired penicillin. (See
         <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">
          "Penicillin allergy: Immediate reactions", section on 'Desensitization'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If penicillin skin testing is not available, the American practice parameter suggests that the selected penicillin can be given using a graded challenge [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="local">
          'Graded challenge (Test dosing)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         Note that it is the author's approach to first (before penicillin skin testing) obtain drug-specific IgE to penicillins (
         <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">
          penicillin G
         </a>
         ,
         <a class="drug drug_general" data-topicid="9751" href="/z/d/drug information/9751.html" rel="external">
          penicillin V
         </a>
         ,
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         , and
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         ) and
         <a class="drug drug_general" data-topicid="9211" href="/z/d/drug information/9211.html" rel="external">
          cefaclor
         </a>
         in subjects who experienced a severe anaphylactic reaction to a cephalosporin, especially cephalothin, cefamandole,
         <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">
          cephalexin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">
          cefadroxil
         </a>
         , and cefaclor, which share similar or identical side chains with penicillins. If these are positive, then skin testing is not performed and alternative antibiotics, including beta-lactams other than penicillins and culprit cephalosporins (eg, carbapenems,
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         , and group A cephalosporins), can be used after an appropriate allergy workup, or the patient can be desensitized. If the penicillin-specific IgE is negative, penicillin skin testing is then performed. However, IgE immunoassays are rarely used in the United States.
        </p>
        <p>
         In studies where penicillins were administered to cephalosporin-allergic subjects presenting negative results in penicillin allergy tests , all individuals tolerated the penicillins concerned (eg, benzylpenicillin, penicillin VK,
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         , and flucloxacillin) [
         <a href="#rid6">
          6,7,27,28,31,35,44,48,51,92
         </a>
         ]. The safety and feasibility of amoxicillin challenges without penicillin skin tests was assessed in 40 patients with anaphylactic reactions to
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         and positive skin tests to it [
         <a href="#rid92">
          92
         </a>
         ]. All 40 patients underwent a three-day amoxicillin challenge without reporting immediate reactions. One patient experienced a delayed benign rash at 24 hours and ceased amoxicillin.
        </p>
        <p class="headingAnchor" id="H1444650201">
         <span class="h2">
          Carbapenems and monobactams
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with immediate cephalosporin allergy usually tolerate carbapenems (eg,
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         ,
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         ,
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         , and doripenem) and monobactams (ie,
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         ) [
         <a href="#rid28">
          28,93
         </a>
         ]. In the largest study available, 98 patients with convincing histories of immediate cephalosporin reactions and positive skin tests to the culprit cephalosporin underwent allergy evaluation and graded challenge with several related medications. Overall, fewer than 5 percent had positive skin tests to carbapenems or monobactams [
         <a href="#rid28">
          28
         </a>
         ]. For ethical reasons, patients with positive skin tests were not challenged to determine if the positive results were true.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Carbapenems share a common four-membered beta-lactam ring with cephalosporins (and penicillins) and hence the potential for cross-sensitization, although clinical cross-reactivity with cephalosporins appears to be rare  (
         <a class="graphic graphic_figure graphicRef79230" href="/z/d/graphic/79230.html" rel="external">
          figure 4
         </a>
         ). In the study mentioned above, only 1 of 98 subjects was skin test positive to both cephalosporins and carbapenems (both
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         and
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         ), and this patient also tested positive to penicillin reagents and
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         . Therefore, his IgE antibodies were probably directed against the beta-lactam ring that is shared by all beta-lactams [
         <a href="#rid28">
          28
         </a>
         ]. In the 97 subjects with negative skin tests to carbapenems, graded challenges were performed with meropenem and imipenem and were well-tolerated by 96 patients. The one remaining subject developed a mild urticarial eruption 30 minutes after the full dose of imipenem.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The author's recommended approach to patients with a history of an immediate reaction to a cephalosporin, who now require a carbapenem, is to perform skin testing with the carbapenem in question. The concentrations used in the study above were
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         at 1 mg/mL and
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         at 0.5 mg/mL for each component [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If skin tests are negative, the carbapenem can be given by graded challenge.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If skin tests are positive, the carbapenem should be given
         <strong>
          only
         </strong>
         if there is no alternative drug and then using a desensitization protocol. (See
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          Aztreonam
         </a>
         is the only monobactam clinically available. Although it contains a monocyclic beta-lactam core, with very rare exceptions [
         <a href="#rid14">
          14,91
         </a>
         ], it does not pose a risk to patients allergic to penicillin. It also does not pose a risk to patients allergic to cephalosporins
         <strong>
          other than
         </strong>
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         . However, clinical cross-reactivity has been reported between aztreonam and ceftazidime, which share an identical R1 side chain group [
         <a href="#rid28">
          28,94,95
         </a>
         ]. Despite the similarity in side chain groups, not all ceftazidime-allergic patients react to aztreonam [
         <a href="#rid28">
          28,96
         </a>
         ], and not all aztreonam-allergic patients react to ceftazidime [
         <a href="#rid97">
          97
         </a>
         ]. Therefore, we suggest that patients who experienced immediate reactions to ceftazidime in the past and now require aztreonam be skin tested to aztreonam at concentrations up to 20 mg/mL [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         skin test results are negative, the patient can receive it by graded challenge.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         skin tests to aztreonam are positive and the patient has a particular need for this drug, then it should be administered using a rapid desensitization protocol. (See
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If an allergy evaluation is not possible, then we suggest informing the patient with a past reaction to
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         that the risk of reacting to
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         is estimated at less than 5 percent [
         <a href="#rid28">
          28
         </a>
         ] and then performing a graded challenge.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3480400696">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109237.html" rel="external">
          "Society guideline links: Drug allergy and hypersensitivity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14737187">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An evaluation for immediate hypersensitivity to cephalosporins is appropriate in any patient who experienced signs of symptoms of immediate allergy shortly (within minutes to a few hours) after receiving a cephalosporin  (
         <a class="graphic graphic_table graphicRef100732" href="/z/d/graphic/100732.html" rel="external">
          table 1
         </a>
         ), as well as patients with isolated urticaria or angioedema regardless of the timing of onset. If the immediate allergy is confirmed, it is still likely that the patient can be demonstrated (through skin testing and graded challenge) to tolerate other beta-lactam drugs, including structurally dissimilar cephalosporins, penicillins, carbapenems, and monobactams. (See
         <a class="local">
          'Allergy evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cross-reactivity among cephalosporins and between cephalosporins and penicillins commonly arises from structural similarities in side chain groups or rarely from sensitization to the core beta-lactam ring (present in both penicillins and cephalosporins) or metabolites of this ring  (
         <a class="graphic graphic_figure graphicRef69298" href="/z/d/graphic/69298.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Allergy evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The allergy evaluation is similar to that for immediate penicillin allergy and is based on skin testing and graded challenge. However, testing for immediate cephalosporin allergy is not as well-validated and reliable as testing for penicillin allergy, for several reasons. In vitro immunoglobulin E (IgE) assays specific to cephalosporins are used in some countries but not in the United States. (See
         <a class="local">
          'Skin testing'
         </a>
         above and
         <a class="local">
          'Graded challenge (Test dosing)'
         </a>
         above and
         <a class="local">
          'In vitro testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An algorithm depicts the approach to identifying a safe alternative cephalosporin in a patient with a past immediate cephalosporin reaction  (
         <a class="graphic graphic_algorithm graphicRef122623" href="/z/d/graphic/122623.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Other cephalosporins'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most patients with immediate reactions to cephalosporins and no history of reacting to penicillins will tolerate penicillins. If a patient reacted to a cephalosporin in the past and now requires a penicillin, then penicillin allergy testing is indicated to guide management as shown  (
         <a class="graphic graphic_algorithm graphicRef122624" href="/z/d/graphic/122624.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Penicillins'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with immediate cephalosporin allergy usually tolerate carbapenems (eg,
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         ,
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         ,
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         , and doripenem). An approach to evaluating such patients, which involves carbapenem skin testing, is described. (See
         <a class="local">
          'Carbapenems and monobactams'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          Aztreonam
         </a>
         is the only monobactam available for clinical use, and there is no evidence of immunologic cross-reactivity between the core cephalosporin structure and monobactams, so most cephalosporin-allergic patients may receive aztreonam normally. An exception is the patient with a past immediate reaction to
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         , because aztreonam and ceftazidime share an identical side chain, and cross-reactivity between the two drugs is reported. An approach to evaluating such patients, which involves aztreonam skin testing, is described. (See
         <a class="local">
          'Carbapenems and monobactams'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Blanca M, Torres MJ, García JJ, et al. Natural evolution of skin test sensitivity in patients allergic to beta-lactam antibiotics. J Allergy Clin Immunol 1999; 103:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Gaeta F, Valluzzi RL, et al. Natural evolution of skin-test sensitivity in patients with IgE-mediated hypersensitivity to cephalosporins. Allergy 2014; 69:806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Gaeta F, Valluzzi RL, et al. Diagnosing hypersensitivity reactions to cephalosporins in children. Pediatrics 2008; 122:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Guéant-Rodriguez RM, Viola M, et al. Diagnosing immediate reactions to cephalosporins. Clin Exp Allergy 2005; 35:1234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pichichero ME, Pichichero DM. Diagnosis of penicillin, amoxicillin, and cephalosporin allergy: reliability of examination assessed by skin testing and oral challenge. J Pediatr 1998; 132:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuson C, Kumar K, Le A, et al. Immediate cephalosporin allergy. Intern Med J 2019; 49:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone CA Jr, Trubiano JA, Phillips EJ. Testing Strategies and Predictors for Evaluating Immediate and Delayed Reactions to Cephalosporins. J Allergy Clin Immunol Pract 2021; 9:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Atanaskovic-Markovic M, Barbaud A, et al. Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper. Allergy 2020; 75:1300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanca M, Vega JM, Garcia J, et al. New aspects of allergic reactions to betalactams: crossreactions and unique specificities. Clin Exp Allergy 1994; 24:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pham NH, Baldo BA. beta-Lactam drug allergens: fine structural recognition patterns of cephalosporin-reactive IgE antibodies. J Mol Recognit 1996; 9:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldo BA. Penicillins and cephalosporins as allergens--structural aspects of recognition and cross-reactions. Clin Exp Allergy 1999; 29:744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanca M, Mayorga C, Torres MJ, et al. Side-chain-specific reactions to betalactams: 14 years later. Clin Exp Allergy 2002; 32:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagakura N, Shimizu T, Masuzawa T, Yanagihara Y. Anti-cephalexin monoclonal antibodies and their cross-reactivities to cephems and penams. Int Arch Allergy Appl Immunol 1990; 93:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Gaeta F, Arribas Poves MF, Valluzzi RL. Cross-Reactivity among Beta-Lactams. Curr Allergy Asthma Rep 2016; 16:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez-Inestrosa E, Suau R, Montañez MI, et al. Cephalosporin chemical reactivity and its immunological implications. Curr Opin Allergy Clin Immunol 2005; 5:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guéant JL, Guéant-Rodriguez RM, Viola M, et al. IgE-mediated hypersensitivity to cephalosporins. Curr Pharm Des 2006; 12:3335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pichichero ME, Zagursky R. Penicillin and cephalosporin allergy. Ann Allergy Asthma Immunol 2014; 112:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zagursky RJ, Pichichero ME. Cross-reactivity in β-Lactam Allergy. J Allergy Clin Immunol Pract 2018; 6:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Picard M, Robitaille G, Karam F, et al. Cross-Reactivity to Cephalosporins and Carbapenems in Penicillin-Allergic Patients: Two Systematic Reviews and Meta-Analyses. J Allergy Clin Immunol Pract 2019; 7:2722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao Z, Baldo BA, Rimmer J. beta-Lactam allergenic determinants: fine structural recognition of a cross-reacting determinant on benzylpenicillin and cephalothin. Clin Exp Allergy 2002; 32:1644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harle DG, Baldo BA. Drugs as allergens: an immunoassay for detecting IgE antibodies to cephalosporins. Int Arch Allergy Appl Immunol 1990; 92:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venemalm L. Pyrazinone conjugates as potential cephalosporin allergens. Bioorg Med Chem Lett 2001; 11:1869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez-Sancho F, Perez-Inestrosa E, Suau R, et al. Synthesis, characterization and immunochemical evaluation of cephalosporin antigenic determinants. J Mol Recognit 2003; 16:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martín-Serrano A, Mayorga C, Barrionuevo E, et al. Design of an antigenic determinant of cefaclor: Chemical structure-IgE recognition relationship. J Allergy Clin Immunol 2020; 145:1301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Gaeta F, Valluzzi RL, et al. IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of alternative cephalosporins. J Allergy Clin Immunol 2015; 136:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trubiano JA, Stone CA, Grayson ML, et al. The 3 Cs of Antibiotic Allergy-Classification, Cross-Reactivity, and Collaboration. J Allergy Clin Immunol Pract 2017; 5:1532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Somech R, Weber EA, Lavi S. Evaluation of immediate allergic reactions to cephalosporins in non-penicillin-allergic patients. Int Arch Allergy Immunol 2009; 150:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Gaeta F, Valluzzi RL, et al. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. J Allergy Clin Immunol 2010; 126:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Quaratino D, Aimone-Gastin I, et al. Cephalosporin allergy: Characterization of unique and cross-reaction cephalosporin antigens. Int J Immunopathol Pharmacol 1997; 10:Suppl 2:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Mayorga C, Torres MJ, et al. Immediate allergic reactions to cephalosporins: cross-reactivity and selective responses. J Allergy Clin Immunol 2000; 106:1177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antunez C, Blanca-Lopez N, Torres MJ, et al. Immediate allergic reactions to cephalosporins: evaluation of cross-reactivity with a panel of penicillins and cephalosporins. J Allergy Clin Immunol 2006; 117:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasdenteufel F, Luyasu S, Renaudin JM, et al. Anaphylactic shock associated with cefuroxime axetil: structure-activity relationships. Ann Pharmacother 2007; 41:1069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varela Losada S, González de la Cuesta C, Alvarez-Eire MG, González González C. Immediate-type allergic reaction to cefuroxime: cross-reactivity with other cephalosporins, and good tolerance to ceftazidime. J Investig Allergol Clin Immunol 2009; 19:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christiansen IS, Krøigaard M, Mosbech H, et al. Clinical and diagnostic features of perioperative hypersensitivity to cefuroxime. Clin Exp Allergy 2015; 45:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Gasse AL, Ebo DG, Faber MA, et al. Cross-reactivity in IgE-mediated allergy to cefuroxime: Focus on the R1 side chain. J Allergy Clin Immunol Pract 2020; 8:1094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010; 105:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miranda A, Blanca M, Vega JM, et al. Cross-reactivity between a penicillin and a cephalosporin with the same side chain. J Allergy Clin Immunol 1996; 98:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sastre J, Quijano LD, Novalbos A, et al. Clinical cross-reactivity between amoxicillin and cephadroxil in patients allergic to amoxicillin and with good tolerance of penicillin. Allergy 1996; 51:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Valluzzi RL, Caruso C, et al. Cross-Reactivity and Tolerability of Cephalosporins in Patients with IgE-Mediated Hypersensitivity to Penicillins. J Allergy Clin Immunol Pract 2018; 6:1662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Guéant-Rodriguez RM, Viola M, et al. Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins. Ann Intern Med 2004; 141:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Viola M, Guéant-Rodriguez RM, et al. Imipenem in patients with immediate hypersensitivity to penicillins. N Engl J Med 2006; 354:2835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Viola M, Guéant-Rodriguez RM, et al. Brief communication: tolerability of meropenem in patients with IgE-mediated hypersensitivity to penicillins. Ann Intern Med 2007; 146:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaeta F, Valluzzi RL, Alonzi C, et al. Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins. J Allergy Clin Immunol 2015; 135:972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uyttebroek AP, Decuyper II, Bridts CH, et al. Cefazolin Hypersensitivity: Toward Optimized Diagnosis. J Allergy Clin Immunol Pract 2016; 4:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warrington RJ, McPhillips S. Independent anaphylaxis to cefazolin without allergy to other beta-lactam antibiotics. J Allergy Clin Immunol 1996; 98:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Igea JM, Fraj J, Davila I, et al. Allergy to cefazolin: study of in vivo cross reactivity with other betalactams. Ann Allergy 1992; 68:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber EA. Cefazolin specific side chain hypersensitivity. J Allergy Clin Immunol 1996; 98:849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pipet A, Veyrac G, Wessel F, et al. A statement on cefazolin immediate hypersensitivity: data from a large database, and focus on the cross-reactivities. Clin Exp Allergy 2011; 41:1602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadleir PH, Clarke RC, Platt PR. Cefalotin as antimicrobial prophylaxis in patients with known intraoperative anaphylaxis to cefazolin. Br J Anaesth 2016; 117:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almeida JP, Lopes A, Campos Melo A, et al. Selective hypersensitivity to cefazolin and contribution of the basophil activation test. Eur Ann Allergy Clin Immunol 2017; 49:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mota I, Gaspar Â, Morais-Almeida M. Perioperative Anaphylaxis Including Kounis Syndrome due to Selective Cefazolin Allergy. Int Arch Allergy Immunol 2018; 177:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sequeira T, Gaspar Â, Mota I, et al. Kounis Syndrome Associated With Selective Anaphylaxis to Cefazolin. J Investig Allergol Clin Immunol 2018; 28:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcos Bravo C, Luna Ortiz I, González Vázquez R. Hypersensitivity to cefuroxime with good tolerance to other betalactams. Allergy 1995; 50:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Quaratino D, Venuti A, et al. Selective type-1 hypersensitivity to cefuroxime. J Allergy Clin Immunol 1998; 101:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Quaratino D, Venemalm L, et al. A case of IgE-mediated hypersensitivity to ceftriaxone. J Allergy Clin Immunol 1999; 104:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Piunti E, Di Fonso M, et al. Selective immediate hypersensitivity to ceftriaxone. Allergy 2000; 55:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demoly P, Messaad D, Sahla H, et al. Immediate hypersensitivity to ceftriaxone. Allergy 2000; 55:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Di Fonso M, Artesani MC, et al. Selective immediate hypersensitivity to ceftazidime. Allergy 2001; 56:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Viola M, Guéant-Rodriguez RM, et al. Selective immediate hypersensitivity to cefodizime. Allergy 2005; 60:1545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atanasković-Marković M, Cirković Velicković T, Gavrović-Jankulović M, et al. A case of selective IgE-mediated hypersensitivity to ceftibuten. Allergy 2005; 60:1454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaig P, San Miguel MM, Enrique E, García-Ortega P. Selective type-1 hypersensitivity to cefixime. Allergy 1999; 54:901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreno E, Dávila I, Laffond E, et al. Selective immediate hypersensitivity to cefepime. J Investig Allergol Clin Immunol 2007; 17:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanca M, Romano A, Torres MJ, et al. Update on the evaluation of hypersensitivity reactions to betalactams. Allergy 2009; 64:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torres MJ, Blanca M, Fernandez J, et al. Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy 2003; 58:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           The diagnosis and management of anaphylaxis. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. J Allergy Clin Immunol 1998; 101:S465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broyles AD, Banerji A, Castells M. Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: General Concepts. J Allergy Clin Immunol Pract 2020; 8:S3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Empedrad R, Darter AL, Earl HS, Gruchalla RS. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. J Allergy Clin Immunol 2003; 112:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Testi S, Severino M, Iorno ML, et al. Nonirritating concentration for skin testing with cephalosporins. J Investig Allergol Clin Immunol 2010; 20:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Gaeta F, Valluzzi RL, et al. Diagnosing nonimmediate reactions to cephalosporins. J Allergy Clin Immunol 2012; 129:1166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Poorten MM, Van Gasse AL, Hagendorens MM, et al. Nonirritating skin test concentrations for ceftazidime and aztreonam in patients with a documented beta-lactam allergy. J Allergy Clin Immunol Pract 2021; 9:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013; 68:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbaud A, Reichert-Penetrat S, Tréchot P, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol 1998; 139:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brockow K, Romano A, Blanca M, et al. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mori F, Liccioli G, Piccorossi A, et al. The Diagnosis of Ceftriaxone Hypersensitivity in a Paediatric Population. Int Arch Allergy Immunol 2019; 178:272.
          </a>
         </li>
         <li class="breakAll">
          Dr. Antonino Romano, unpublished data.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JE, Kim SH, Jin HJ, et al. IgE Sensitization to Cephalosporins in Health Care Workers. Allergy Asthma Immunol Res 2012; 4:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Gasse AL, Sabato V, Degerbeck F, et al. Specific IgE to cefazolin: Does it benefit diagnosis? J Allergy Clin Immunol Pract 2019; 7:2932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanz ML, Gamboa PM, Antépara I, et al. Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics. Clin Exp Allergy 2002; 32:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torres MJ, Padial A, Mayorga C, et al. The diagnostic interpretation of basophil activation test in immediate allergic reactions to betalactams. Clin Exp Allergy 2004; 34:1768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ebo DG, Sainte-Laudy J, Bridts CH, et al. Flow-assisted allergy diagnosis: current applications and future perspectives. Allergy 2006; 61:1028.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abuaf N, Rostane H, Rajoely B, et al. Comparison of two basophil activation markers CD63 and CD203c in the diagnosis of amoxicillin allergy. Clin Exp Allergy 2008; 38:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Week AL, Sanz ML, Gamboa PM, et al. Diagnosis of immediate-type beta-lactam allergy in vitro by flow-cytometric basophil activation test and sulfidoleukotriene production: a multicenter study. J Investig Allergol Clin Immunol 2009; 19:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SY, Kim JH, Jang YS, et al. The Basophil Activation Test Is Safe and Useful for Confirming Drug-Induced Anaphylaxis. Allergy Asthma Immunol Res 2016; 8:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uyttebroek AP, Sabato V, Cop N, et al. Diagnosing cefazolin hypersensitivity: Lessons from dual-labeling flow cytometry. J Allergy Clin Immunol Pract 2016; 4:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayorga C, Ebo DG, Lang DM, et al. Controversies in drug allergy: In vitro testing. J Allergy Clin Immunol 2019; 143:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Executive summary of disease management of drug hypersensitivity: a practice parameter. Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, the American Academy of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1999; 83:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003; 58:854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blumenthal KG, Shenoy ES, Wolfson AR, et al. Addressing inpatient beta-lactam allergies: A multi-hospital implementation. J Allergy Clin Immunol Pract 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iammatteo M, Blumenthal KG, Saff R, et al. Safety and outcomes of test doses for the evaluation of adverse drug reactions: a 5-year retrospective review. J Allergy Clin Immunol Pract 2014; 2:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan DA, Solensky R. Drug allergy. J Allergy Clin Immunol 2010; 125:S126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Valluzzi RL, Caruso C, et al. Tolerability of Cefazolin and Ceftibuten in Patients with IgE-Mediated Aminopenicillin Allergy. J Allergy Clin Immunol Pract 2020; 8:1989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, Green SL, Krupowicz BA, et al. Cross-reactivity to penicillins in cephalosporin anaphylaxis. Br J Anaesth 2019; 123:e532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kula B, Djordjevic G, Robinson JL. A systematic review: can one prescribe carbapenems to patients with IgE-mediated allergy to penicillins or cephalosporins? Clin Infect Dis 2014; 59:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez Pimiento A, Gómez Martínez M, Mínguez Mena A, et al. Aztreonam and ceftazidime: evidence of in vivo cross allergenicity. Allergy 1998; 53:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adkinson NF Jr. Immunogenicity and cross-allergenicity of aztreonam. Am J Med 1990; 88:12S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moss RB. Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis. J Allergy Clin Immunol 1991; 87:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iglesias Cadarso A, Sáez Jiménez SA, Vidal Pan C, Rodriguez Mosquera M. Aztreonam-induced anaphylaxis. Lancet 1990; 336:746.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13536 Version 17.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10329829" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Natural evolution of skin test sensitivity in patients allergic to beta-lactam antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24673580" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Natural evolution of skin-test sensitivity in patients with IgE-mediated hypersensitivity to cephalosporins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18762521" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Diagnosing hypersensitivity reactions to cephalosporins in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16164453" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Diagnosing immediate reactions to cephalosporins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9470015" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Diagnosis of penicillin, amoxicillin, and cephalosporin allergy: reliability of examination assessed by skin testing and oral challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30667130" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Immediate cephalosporin allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32822918" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Testing Strategies and Predictors for Evaluating Immediate and Delayed Reactions to Cephalosporins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31749148" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8087651" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : New aspects of allergic reactions to betalactams: crossreactions and unique specificities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9131470" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : beta-Lactam drug allergens: fine structural recognition patterns of cephalosporin-reactive IgE antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10336588" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Penicillins and cephalosporins as allergens--structural aspects of recognition and cross-reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11929481" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Side-chain-specific reactions to betalactams: 14 years later.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2099340" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Anti-cephalexin monoclonal antibodies and their cross-reactivities to cephems and penams.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26898316" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Cross-Reactivity among Beta-Lactams.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15985814" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Cephalosporin chemical reactivity and its immunological implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17017928" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : IgE-mediated hypersensitivity to cephalosporins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24767695" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Penicillin and cephalosporin allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29017833" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Cross-reactivity inβ-Lactam Allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31170539" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Cross-Reactivity to Cephalosporins and Carbapenems in Penicillin-Allergic Patients: Two Systematic Reviews and Meta-Analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12569987" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : beta-Lactam allergenic determinants: fine structural recognition of a cross-reacting determinant on benzylpenicillin and cephalothin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2083978" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Drugs as allergens: an immunoassay for detecting IgE antibodies to cephalosporins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11459649" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pyrazinone conjugates as potential cephalosporin allergens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12833570" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Synthesis, characterization and immunochemical evaluation of cephalosporin antigenic determinants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31821817" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Design of an antigenic determinant of cefaclor: Chemical structure-IgE recognition relationship.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25930196" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of alternative cephalosporins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28843343" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The 3 Cs of Antibiotic Allergy-Classification, Cross-Reactivity, and Collaboration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19494517" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Evaluation of immediate allergic reactions to cephalosporins in non-penicillin-allergic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20888035" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Cephalosporin allergy: Characterization of unique and cross-reaction cephalosporin antigens
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11112903" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Immediate allergic reactions to cephalosporins: cross-reactivity and selective responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16461141" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Immediate allergic reactions to cephalosporins: evaluation of cross-reactivity with a panel of penicillins and cephalosporins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17488833" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Anaphylactic shock associated with cefuroxime axetil: structure-activity relationships.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19476025" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Immediate-type allergic reaction to cefuroxime: cross-reactivity with other cephalosporins, and good tolerance to ceftazidime.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25395022" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clinical and diagnostic features of perioperative hypersensitivity to cefuroxime.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31479769" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Cross-reactivity in IgE-mediated allergy to cefuroxime: Focus on the R1 side chain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20934625" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Drug allergy: an updated practice parameter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8828545" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Cross-reactivity between a penicillin and a cephalosporin with the same side chain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8837660" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clinical cross-reactivity between amoxicillin and cephadroxil in patients allergic to amoxicillin and with good tolerance of penicillin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29408440" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Cross-Reactivity and Tolerability of Cephalosporins in Patients with IgE-Mediated Hypersensitivity to Penicillins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15238366" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16807429" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Imipenem in patients with immediate hypersensitivity to penicillins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17310050" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Brief communication: tolerability of meropenem in patients with IgE-mediated hypersensitivity to penicillins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25457154" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27317018" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Cefazolin Hypersensitivity: Toward Optimized Diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8757224" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Independent anaphylaxis to cefazolin without allergy to other beta-lactam antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1376972" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Allergy to cefazolin: study of in vivo cross reactivity with other betalactams.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8876565" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Cefazolin specific side chain hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22093010" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A statement on cefazolin immediate hypersensitivity: data from a large database, and focus on the cross-reactivities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28077533" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Cefalotin as antimicrobial prophylaxis in patients with known intraoperative anaphylaxis to cefazolin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28294589" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Selective hypersensitivity to cefazolin and contribution of the basophil activation test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29913447" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Perioperative Anaphylaxis Including Kounis Syndrome due to Selective Cefazolin Allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30073957" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Kounis Syndrome Associated With Selective Anaphylaxis to Cefazolin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7573820" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Hypersensitivity to cefuroxime with good tolerance to other betalactams.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9564816" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Selective type-1 hypersensitivity to cefuroxime.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10550764" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A case of IgE-mediated hypersensitivity to ceftriaxone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10782539" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Selective immediate hypersensitivity to ceftriaxone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10782542" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Immediate hypersensitivity to ceftriaxone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11167362" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Selective immediate hypersensitivity to ceftazidime.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16266391" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Selective immediate hypersensitivity to cefodizime.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16197484" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A case of selective IgE-mediated hypersensitivity to ceftibuten.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10485404" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Selective type-1 hypersensitivity to cefixime.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17323865" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Selective immediate hypersensitivity to cefepime.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19133923" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Update on the evaluation of hypersensitivity reactions to betalactams.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14510712" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Diagnosis of immediate allergic reactions to beta-lactam antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9673591" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : The diagnosis and management of anaphylaxis. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32791249" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: General Concepts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13679828" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20461975" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Nonirritating concentration for skin testing with cephalosporins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22322006" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Diagnosing nonimmediate reactions to cephalosporins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32889219" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Nonirritating skin test concentrations for ceftazidime and aztreonam in patients with a documented beta-lactam allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23617635" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9764148" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The use of skin testing in the investigation of cutaneous adverse drug reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11991289" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : General considerations for skin test procedures in the diagnosis of drug hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30605910" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : The Diagnosis of Ceftriaxone Hypersensitivity in a Paediatric Population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30605910" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : The Diagnosis of Ceftriaxone Hypersensitivity in a Paediatric Population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22379603" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : IgE Sensitization to Cephalosporins in Health Care Workers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31229452" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Specific IgE to cefazolin: Does it benefit diagnosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11929494" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15544603" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The diagnostic interpretation of basophil activation test in immediate allergic reactions to betalactams.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16918504" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Flow-assisted allergy diagnosis: current applications and future perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18331364" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Comparison of two basophil activation markers CD63 and CD203c in the diagnosis of amoxicillin allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19476013" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Diagnosis of immediate-type beta-lactam allergy in vitro by flow-cytometric basophil activation test and sulfidoleukotriene production: a multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27582406" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The Basophil Activation Test Is Safe and Useful for Confirming Drug-Induced Anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27836066" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Diagnosing cefazolin hypersensitivity: Lessons from dual-labeling flow cytometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30573343" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Controversies in drug allergy: In vitro testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10616910" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Executive summary of disease management of drug hypersensitivity: a practice parameter. Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, the American Academy of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12911412" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Addressing inpatient beta-lactam allergies: A multi-hospital implementation
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25439369" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Safety and outcomes of test doses for the evaluation of adverse drug reactions: a 5-year retrospective review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20176256" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Drug allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32145403" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Tolerability of Cefazolin and Ceftibuten in Patients with IgE-Mediated Aminopenicillin Allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31604573" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Cross-reactivity to penicillins in cephalosporin anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25048853" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : A systematic review: can one prescribe carbapenems to patients with IgE-mediated allergy to penicillins or cephalosporins?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9689350" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Aztreonam and ceftazidime: evidence of in vivo cross allergenicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2316554" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Immunogenicity and cross-allergenicity of aztreonam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1991925" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1975914" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Aztreonam-induced anaphylaxis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
